Coutre S, et al. - This phase 2 study prospectively evaluated venetoclax in patients with refractory to/relapses after (R/R) chronic lymphocytic leukemia (CLL) following ibrutinib or idelalisib therapy; here researchers reported on patients who received idelalisib as the last B-cell receptor pathway inhibitors (BCRi) prior to enrollment. In patients with CLL whose disease progressed during or after idelalisib therapy, venetoclax confirmed to have promising clinical activity and favorable tolerability.